Database Query Results : , , TumCMig

TumCMig, Tumor cell migration: Click to Expand ⟱
Source:
Type:
Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body.
Scientific Papers found: Click to Expand⟱
253- AL,    Allicin inhibits invasion and migration of breast cancer cells through the suppression of VCAM-1: Regulation of association between p65 and ER-α
- in-vitro, BC, MDA-MB-231
TumCMig↓, ERK↓, VCAM-1↓, NF-kB↓,
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
276- ALA,    Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B
P53↑, EMT↓, AMPK↑, cycD1/CCND1↓, TumCMig↓,
295- ALA,    α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells
- in-vitro, Bladder, T24
ITGB1↓, TumCMig↓, ERK↓, Akt↓,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
3442- ALA,    α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B - in-vitro, Nor, 3T3
tumCV↓, TumCMig↓, TumCI↓, ROS↑, Hif1a↑, JNK↑, Casp↑, TumCCA↑, Apoptosis↑, selectivity↑,
553- Anamu,    The anti-inflammatory and analgesic effects of a crude extract of Petiveria alliacea L. (Phytolaccaceae)
- in-vivo, NA, NA
TumCMig↓,
1157- And,    Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression
- in-vitro, GBM, GBM8401 - in-vitro, GBM, U251
TumCI↓, TumCMig↓, MMP2↓, ERK↝,
1093- And,    Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells
- in-vitro, Lung, A549
TGF-β↓, TumCMig↓, MMP2↓, MMP9↓, ECM/TCF↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓, p‑ERK↓, ROS↓, NOX4↓, SOD2↑, SIRT1↑, FOXO3↑,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
1548- Api,    A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms
- Review, Colon, NA
*BioAv↓, *Half-Life∅, selectivity↑, *toxicity↓, Wnt/(β-catenin)↓, P53↑, P21↑, PI3K↓, Akt↓, mTOR↓, TumCCA↑, TumCI↓, TumCMig↓, STAT3↓, PKM2↓, EMT↓, cl‑PARP↑, Casp3↑, Bax:Bcl2↑, VEGF↓, Hif1a↓, Dose∅, GLUT1↓, GlucoseCon↓,
1565- Api,    Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B - in-vitro, Lung, H1975
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, Cyt‑c↑, MDA↑, GSH↓, ROS↑, PI3K↓, Akt↓, mTOR↓,
2593- Api,    Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo
- in-vivo, BC, 4T1
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,
2632- Api,    Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress
- in-vitro, EC, NA
TumCP↓, TumCCA↑, Apoptosis↑, Bcl-2↓, BAX↑, Bak↑, Casp↑, ER Stress↑, Ca+2↑, ATF4↑, CHOP↑, ROS↑, MMP↓, TumCMig↓, TumCI↓, eff↑, P53↑, P21↑, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-xL↓,
2641- Api,    Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
TumCMig↓, TumCI↓, ITGB4↓,
3396- ART/DHA,    Progress on the study of the anticancer effects of artesunate
- Review, Var, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, Diff↑, TumAuto↑, angioG↓, TumCCA↑, ROS↑, AMPK↑, mTOR↑, ChemoSen↑, Tf↑, Ferroptosis↑, Ferritin↓, lipid-P↑, CDK1↑, CDK2↑, CDK4↑, CDK6↑, SIRT1↑, COX2↓, IL1β↓, survivin↓, DNAdam↑, RadioS↑,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
574- ART/DHA,    Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway
TumCP↓, TumCMig↓, TumCI↓, MMP17↓, p‑EGFR↓, p‑Akt↓,
570- ART/DHA,    Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling
- vitro+vivo, NSCLC, A549 - vitro+vivo, NSCLC, H1299
TumCCA↑, CSCs↓, TumCI↓, TumCMig↓, TumCG↓, Wnt/(β-catenin)↓, Nanog↓, SOX2↓, OCT4↓, N-cadherin↓, Vim↓, E-cadherin↑,
1333- AS,    Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, Ki-67↓, TumCP↓, Snail↓, Vim↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓,
1362- Ash,  GEM,    Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
- in-vitro, PC, PANC1 - in-vitro, PC, Hs766t
ChemoSen↑, ROS↑, Apoptosis↑, TumCMig↓, F-actin↓, YMcells↓, NF-kB↓,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,
1179- Ash,    Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCP↓, TumCMig↓, STAT3↓, TumVol↓, TumW↓,
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,
3174- Ash,    Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
NF-kB↓, angioG↓, Inflam↓, TumCP↓, TumCMig↓, TumCI↓, Sp1/3/4↓, VEGF↓, angioG↓, uPA↓, PDGF↓, MCP1↓, ICAM-1↓, *NRF2↑, *hepatoP↑,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4810- ASTX,    Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, selectivity↑, *BDNF↑, *ROS↓, *TNF-α↓, *IL6↓, *IFN-γ↓, *NF-kB↓, BAX⇅, Bcl-2↓, *antiOx↑, radioP↑, ChemoSen↑,
4811- ASTX,    Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma
- vitro+vivo, Melanoma, A375 - vitro+vivo, Melanoma, A2058
ROS↓, MMPs↓, TumCMig↓, TumMeta↓, TumCCA↑, antiOx↑, MMP1↓, MMP2↓, MMP9↓,
4980- ATV,    A review of effects of atorvastatin in cancer therapy
- Review, Var, NA
HMG-CoA↓, TumCP↓, TumCMig↓,
1098- BA,    Baicalein inhibits fibronectin-induced epithelial–mesenchymal transition by decreasing activation and upregulation of calpain-2
- in-vitro, Nor, MCF10 - in-vivo, NA, NA
*TumCMig↓, *F-actin↓, *E-cadherin↑, *ZO-1↑, *N-cadherin↓, *Vim↓, *Snail↓, *cal2↓, *Ca+2↝,
2047- BA,    Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells
- in-vitro, CRC, T24 - in-vitro, Nor, SV-HUC-1 - in-vitro, Bladder, 5637 - in-vivo, NA, NA
HDAC↓, AntiTum↑, TumCMig↓, AMPK↑, mTOR↑, TumAuto↑, ROS↑, miR-139-5p↑, BMI1↓, TumCI?, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, PINK1↑, PARK2↑, TumMeta↓, TumCG↓, LC3II↑, p62↓, eff↓,
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2615- Ba,    The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
- Review, Var, NA
*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,
2289- Ba,  Rad,    Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A
- in-vitro, ESCC, KYSE150
TumCP↓, TumCMig↓, Glycolysis↓, cycD1/CCND1↓, CDK4↓, ECAR↓, TumCCA↑, HK1↓, ALDH↓, ALDOA↓, PKM2↓, Hif1a↓,
2473- BA,    Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B - in-vitro, Lung, H460
EMT↓, PDK1↓, Akt↓, TumCMig↓, E-cadherin↑, Vim↓,
1398- BBR,    Berberine inhibits the progression of renal cell carcinoma cells by regulating reactive oxygen species generation and inducing DNA damage
- in-vitro, Kidney, NA
TumCP↓, TumCMig↓, ROS↑, Apoptosis↑, BAX↑, BAD↑, Bak↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp9↑, E-cadherin↑, TIMP1↑, γH2AX↑, Bcl-2↓, N-cadherin↓, Vim↓, Snail↓, RAD51↓, PCNA↓,
1392- BBR,    Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress
- in-vitro, GC, AGS - in-vitro, GC, MKN45
TumCG↓, TumCMig↓, ROS↑, MDA↑, SOD↓, NRF2↓, HO-1↓, Hif1a↓, EMT↓, Snail↓, Vim↓,
2700- BBR,    Cell-specific pattern of berberine pleiotropic effects on different human cell lines
- in-vitro, GBM, U343 - in-vitro, GBM, MIA PaCa-2 - in-vitro, Nor, HDFa
selectivity↑, TumCCA↑, Casp3↑, TumCI↓, TumCMig↓, N-cadherin?, DNMT1↑,
2702- BBR,    The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
- in-vitro, Lung, A549 - in-vitro, Lung, H1975
TumCG↓, MAPK↓, FOXO3↑, TumCCA↑, TumCMig↓, TumCI↓, Sp1/3/4↓, PDK1↓, DNMT1↓, eff↑,
2709- BBR,    Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α
- in-vitro, HCC, HepG2
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PKM2↓, LDHA↓,
2711- BBR,    Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
2682- BBR,    Berberine Inhibited Growth and Migration of Human Colon Cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions
- in-vitro, CRC, HT29 - in-vitro, CRC, SW480 - in-vitro, CRC, HCT116
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, necrosis↑, AQPs↓, PTEN↑, PI3K↓, Akt↓, p‑Akt↓, mTOR↓, p‑mTOR↓,
1102- BBR,    Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells
- in-vitro, Melanoma, B16-BL6
TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,
2742- BetA,    Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, 4T1 - in-vitro, BC, MCF-7
tumCV↓, TumCMig↓, TumCI↓, STAT3↑, FAK↓, MMPs↓, MMP2↓, MMP9↓, TIMP2↑,
2756- BetA,    Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway
- in-vitro, HCC, HUH7 - in-vitro, HCC, H1299
TumCP↓, ROS↓, antiOx↓, TumCG↓, TumCMig↓, NRF2↓, GPx4↓, HO-1↓, NCOA4↑, FTH1↓, Ferritin↑, Ferroptosis↑, GSH↓, MDA↓,
2757- BetA,    Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways
- in-vitro, GBM, U251
tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, Ferroptosis↑, HO-1↑, NRF2↑,
2741- BetA,    Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress
- in-vitro, GC, SNU16 - in-vitro, GC, NCI-N87 - in-vivo, NA, NA
TumCG↓, TumCMig↓, TumCI↓, N-cadherin↓, E-cadherin↑, EMT↓, Ki-67↓, MMP2↓,
2719- BetA,    Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential
- in-vitro, CRC, T24 - in-vitro, Bladder, UMUC3 - in-vitro, Bladder, 5637
TumCD↑, Apoptosis↑, TumCCA↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK2↓, CDC25↓, mtDam↑, BAX↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Snail↓, Slug↓, MMP9↓, selectivity↑, MMP↓, ROS∅, TumCMig↓, TumCI↓,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
2730- BetA,    Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells
- in-vitro, Bladder, T24
tumCV↓, TumCP↓, TumCMig↓, Casp↑, TumAuto↑, LC3B-II↑, p‑AMPK↑, mTOR↓, BMI1↓, ROS↑, eff↓,
722- Bor,    Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms
- in-vitro, Ovarian, MDAH-2774
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, ROS↑, miR-21↓, miR-130a↓, Casp8∅, Casp10∅, cycD1/CCND1∅, CDK6∅, CDK4∅, FADD∅, DR4∅, DR5∅,
709- Bor,    Cellular changes in boric acid-treated DU-145 prostate cancer cells
- in-vitro, Pca, DU145
Cyc↓, MAPK↓, TumCMig↓, LAMP2↓, p‑ERK⇅, TumCM/A↑,
702- Bor,  GEN,  SeMet,  Rad,    Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States)
- Analysis, NA, NA
Risk↓, TumCMig↓, Bcl-2↓,
696- Bor,    Nothing Boring About Boron
- Review, Var, NA
*hs-CRP↓, *TNF-α↓, *SOD↑, *Catalase↑, *GPx↑, *cognitive↑, *memory↑, *Risk↓, *SAM-e↑, *NAD↝, *ATP↝, *Ca+2↝, HDAC↓, TumVol↓, IGF-1↓, PSA↓, Cyc↓, TumCMig↓, *serineP↓, HIF-1↓, *ChemoSideEff↓, *VitD↑, *Mag↑, *eff↑, Risk↓, *Inflam↓, *neuroP↑, *Calcium↑, *BMD↑, *chemoP↑, AntiCan↑, *Dose↑, *Dose↝, *BMPs↑, *testos↑, angioG↓, Apoptosis↑, *selectivity↑, *chemoPv↑,
1416- Bos,    Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent
- Review, NA, NA
5LO↓, TumCCA↑, LC3B↓, PI3K↓, Akt↓, Glycolysis↓, AMPK↑, mTOR↓, Let-7↑, COX2↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, HIF-1↓, angioG↓, TumCP↓, TumCMig↓, NF-kB↓,
2768- Bos,    Boswellic acids as promising agents for the management of brain diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*neuroP↑, *ROS↓, *cognitive↓, TumCP↓, TumCMig↓, TumMeta↓, angioG↓, Apoptosis↑, *Inflam↓, IL1↓, IL2↓, IL4↓, IL6↓, TNF-α↓, P53↑, Akt↓, NF-kB↓, DNAdam↑, Casp↑, COX2↓, MMP9↓, CXCR4↓, VEGF↓, *SOD↑, *Catalase↑, *GPx↑, *NRF2↑,
1651- CA,  PBG,    Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer
- Review, Var, NA
Apoptosis↑, TumCCA↓, TumCMig↓, TumMeta↓, ChemoSen↑, eff↑, eff↑, eff↓, eff↝, Dose∅, AMPK↑, p62↓, LC3II↑, Ca+2↑, Bax:Bcl2↑, CDK4↑, CDK6↑, RB1↑, EMT↓, E-cadherin↑, Vim↓, β-catenin/ZEB1↓, NF-kB↓, angioG↑, VEGF↓, TSP-1↑, MMP9↓, MMP2↓, ChemoSen↑, eff↑, ROS↑, CSCs↓, Fas↑, P53↑, BAX↑, Casp↑, β-catenin/ZEB1↓, NDRG1↑, STAT3↓, MAPK↑, ERK↑, eff↑, eff↑, eff↑,
1207- CA,  PacT,    Caffeine inhibits the anticancer activity of paclitaxel via down-regulation of α-tubulin acetylation
- in-vitro, Lung, A549 - in-vitro, Cerv, HeLa
TumCG↑, TumCMig↓, Apoptosis↓, ac‑α-tubulin↑,
1264- CAP,    Capsaicin modulates proliferation, migration, and activation of hepatic stellate cells
- in-vitro, HCC, NA
TumCP↓, TumCMig↓, TumCCA↑, MMP∅, MMP2↓, MMP9↓, α-SMA↓, COL1A1↓, COL3A1↓, TIMP1↓,
1263- CAP,    Capsaicin inhibits the migration and invasion via the AMPK/NF-κB signaling pathway in esophagus sequamous cell carcinoma by decreasing matrix metalloproteinase-9 expression
- in-vitro, ESCC, Eca109
TumCMig↓, TumCI↓, MMP9↓, p‑AMPK↑, SIRT1↑, NF-kB↓, p‑IκB↑,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1/CCND1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
1518- CAP,    Capsaicin-mediated tNOX (ENOX2) up-regulation enhances cell proliferation and migration in vitro and in vivo
- in-vitro, CRC, HCT116
ENOX2↑, TumCP↑, TumCMig↑, Dose?, eff↑,
1103- CBD,    Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway
- vitro+vivo, NA, NA
Apoptosis↑, TumCP↓, TumCMig↓, TumMeta↓, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, Hif1a↓, Wnt/(β-catenin)↓, AXIN1↑, TumVol↓, TumW↓,
1105- CEL,    Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis
- in-vitro, BC, NA
COX2↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓, miR-145↑, TGF-β↓, SMAD3↓,
1106- CGA,    Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6
- vitro+vivo, BC, MCF-7
E-cadherin↑, ZO-1↑, Zeb1↓, N-cadherin↓, Vim↓, Snail↓, Slug↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, LRP6↓, p‑LRP6↓, β-catenin/ZEB1↓, TumVol↓, TumW↓,
4489- Chit,  Se,    Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy
- in-vitro, GBM, U87MG
TumCG↓, TumCMig↓, TumCI↓, ChemoSen↑, *BBB↑, eff↑, eff↑, eff↑, selectivity↑, MMP2↓, MMP9↓, EPR↑,
3258- CHr,  PBG,    Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells
- in-vitro, GC, MKN45
TET1↑, Apoptosis↑, TumCI↓, TumCMig↓,
2590- CHr,    Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway
- in-vitro, GBM, T98G - in-vitro, GBM, U251 - in-vitro, GBM, U87MG
TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
1584- Citrate,    Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations
- in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1
tumCV↓, i-Ca+2↓, TumCMig↓, CD133↓, pH↑, eff↑, Ki-67↓, eff↑,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
4709- CUR,    Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
- Review, Var, NA
miR-21↓, TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-99↑, JAK↓, STAT↓, cycD1/CCND1↓, P21↑, ChemoSen↑, miR-192-5p↑, cMyc↓, Wnt↓, β-catenin/ZEB1↓, miR-130a↓,
4710- CUR,    Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway
- in-vitro, Lung, A549
TumCMig↓, TumCI↓, miR-206↑, p‑mTOR↓, p‑Akt↓,
405- CUR,  5-FU,    Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis
- vitro+vivo, CRC, HCT116
Apoptosis↑, TumCMig↓, NRF2↑, ROS↑, MET↑, miR-34a↑,
461- CUR,    Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, miR-30a-5p↑, PCLAF↓, Bcl-2↓, Casp3↓, BAX↑, cl‑Casp3↑,
476- CUR,    The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer
- in-vitro, PC, PATU-8988 - in-vitro, PC, PANC1
TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,
446- CUR,    The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A Possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells
- in-vitro, CRC, SW480
IR↓, IGF-1↓, Myc↓, TumCMig↓, TumCP↓,
447- CUR,  OXA,    Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway
- vitro+vivo, CRC, HCT116
p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,
450- CUR,    Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT8
TumCP↓, TumCMig↓, CD44↓, CSCs↓,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
454- CUR,    Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway
- in-vitro, GC, MGC803
TumCMig↓, TumCP↓, ROS↑, mtDam↑, DNAdam↑, Apoptosis↑, ATR↑, P21↑, p‑P53↑, GADD45A↑, p‑γH2AX↑,
455- CUR,    Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin
- in-vitro, GC, SGC-7901
Shh↓, Gli1↓, FOXM1↓, β-catenin/ZEB1↓, TumCMig↓, Apoptosis↑, TumCCA↑, Wnt↓, EMT↓, E-cadherin↑, Vim↓,
456- CUR,    Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells
- vitro+vivo, GC, SGC-7901
miR-34a↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, Bcl-2↓, CDK4/6↓, cycD1/CCND1↓,
479- CUR,    Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments
- in-vitro, Tong, CAL27
TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, Bcl-2↓, BAX↑, cl‑Casp3↑,
480- CUR,    Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells
- in-vitro, GBM, SNB19
TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, NEDD9↓, NOTCH1↓, p‑Akt↓,
1445- Deg,    Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model
- in-vivo, lymphoma, NA - in-vitro, lymphoma, NA
Akt↓, TumCP↓, TumCMig↓, VEGF↓, TumCG↓, OS↑,
1446- Deg,    Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells
- in-vitro, BC, 4T1
cMET↓, p‑ERK↓, p‑Akt↓, TumCMig↓, TumCG↓, Weight∅, *toxicity∅, Hif1a↓, TumMeta↓,
1109- DHA,    DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells
- in-vitro, BC, NA
GREM1↓, TumCMig↓, p‑ERK↓, EMT↓,
5008- DSF,  Cu,    Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
- in-vitro, HCC, NA
selectivity↑, TumCD↑, TumCMig↓, TumCI↓, angioG↓, mtDam↑, Iron↑, lipid-P↑, Ferroptosis↑, NF-kB↑, p‑p62↑, Keap1↓, eff↑, eff↓, ChemoSen↑,
4916- DSF,  Cu,    The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics
- Review, Var, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Imm↑, ROS↑, NF-kB↓, chemoP↑, JNK↑, FOXO↑, Myc↑, TumCCA↑, Apoptosis↑, RadioS↑, PD-L1↑, eff↑, CSCs↓, Dose↝, Half-Life↑,
4832- EA,    Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
*antiOx↑, *AntiCan↑, TumCMig↓, angioG↓, ChemoSen↑, RadioS↑, *chemoP↑, *BioAv↓, eff↓, selectivity↑, MMP2↓, MMP9↓, VEGF↓, TumCCA↑, Apoptosis↑, ROS↑, BioAv↑,
1618- EA,    A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action
- Review, BC, NA
TumCCA↑, TumCMig↓, TumCI↓, TumMeta↓, Apoptosis↑, TGF-β↓, SMAD3↓, CDK6↓, PI3K↓, Akt↓, angioG↓, VEGFR2↓, MAPK↓, NEDD9↓, NF-kB↓, eff↑, eff↑, RadioS↑, ChemoSen↑, DNAdam↑, eff↑, *toxicity∅, *toxicity∅,
1111- EDM,    Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓,
1072- EGCG,    Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways
- in-vitro, Thyroid, 8505C
EMT↓, TumCI↓, TumCMig↓, TGF-β↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓,
651- EGCG,    Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
ROS↑, p‑AMPK↑, mTOR↓, FAK↓, Smo↓, Gli1↓, HH↓, TumCMig↓, TumCI↓, NOTCH↓, JAK↓, STAT↓, Bcl-2↓, Bcl-xL↓, BAX↑, Casp9↑,
665- EGCG,    Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway
- in-vitro, NA, H1299
AMPK↑, TumCP↓, TumCMig↓, TumCI↓,
688- EGCG,  GEM,    Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine
- in-vitro, PC, NA
Zeb1↓, β-catenin/ZEB1↓, Vim↓, Akt↓, p‑IGFR↓, TumCG↓, TumCMig↓, TumCI↓,
4685- EGCG,    Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines
- in-vitro, NPC, TW01 - in-vitro, NPC, TW06
CSCs↓, EMT↓, TumCMig↓, TumCI↓, OCT4↓, Snail↓, Vim↓, E-cadherin↓, HSP70/HSPA5↓, HSP90↓, AntiTum↓,
1319- EMD,    Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
- in-vitro, Thyroid, TPC-1 - in-vitro, Thyroid, IHH4
NF-kB↓, TLR4↓, TumCI↓, TumCMig↓,
1247- EMD,    Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition
- vitro+vivo, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,
2455- erastin,    Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments
- in-vitro, Cerv, HeLa
xCT↓, GSH↓, ROS↑, TumCMig↓,
1114- F,    The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study
- vitro+vivo, NA, NA
tumCV↓, TumCMig↓, VEGF↓, EMT↓, Apoptosis↑,
1656- FA,    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
- Review, Var, NA
tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,
1655- FA,    Ferulic acid inhibiting colon cancer cells at different Duke’s stages
- in-vitro, Colon, SW480 - in-vitro, Colon, Caco-2 - in-vitro, Colon, HCT116
TumCP↓, TumCMig↓, TumCCA↑, Apoptosis↑, ATM↑, Chk2↑, ATR↑, CHK1↑, CK2↓, cycA1/CCNA1↑, CDK4↓, CDK6↓, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
1113- FIS,    Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓, CSCs↓,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
2840- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- NA, CCA, NA
ROS↑, TumCMig↓, TumCP↓,
4023- FulvicA,    Shilajit (Mumio) Elicits Apoptosis and Suppresses Cell Migration in Oral Cancer Cells through Targeting Urokinase-type Plasminogen Activator and Its Receptor and Chemokine Signaling Pathways
- in-vitro, Oral, NA
tumCV↓, selectivity↑, Apoptosis↑, uPA↓, TumCMig↓, Dose↝, CXCc↓,
830- GAR,    Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells
- in-vitro, CRC, HT-29
TumCI↓, TumCMig↓, Apoptosis↑, p‑FAK↓, Src↓, MAPK↓, ERK↓, PI3K/Akt↓, Bax:Bcl2↑, Cyt‑c↑, MMP7↓,
817- GAR,    Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways
- vitro+vivo, SCC, KYSE150 - vitro+vivo, SCC, KYSE450
HATs↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, CBP↓, p300↓, TGF-β↓, Ki-67↓, SMAD2↓, SMAD3↓,
806- GAR,    Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin
- vitro+vivo, Pca, HeLa - vitro+vivo, Cerv, SiHa
TumCI↓, TumCMig↓, TumCCA↑, Apoptosis↑, T-cadherin↑,
1186- Gb,    Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis
- in-vitro, PC, NA - in-vitro, Nor, HUVECs - in-vivo, PC, NA
tumCV↓, *toxicity∅, TumCMig↓, TumCI↓, Apoptosis↑, AMPK↑, lipoGen↓, ACC↓, FASN↓,
1189- Gb,    New insight into the mechanisms of Ginkgo biloba leaves in the treatment of cancer
- Review, NA, NA
Apoptosis↑, TumCP↓, TumCI↓, TumCMig↓, Inflam↓, antiOx↑, angioG↓,
1118- Ge,    Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway
- in-vitro, Bladder, T24 - in-vitro, Bladder, 5637
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Vim↓, Slug↓, E-cadherin↑, ZO-1↑, p‑SMAD2↓, p‑SMAD3↓, p‑Akt↓, p‑ERK↓, p‑p38↓,
1240- Ge,  PACs,    Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, Hs294T
TumCMig↓, TumCI↓, COX2↓, PGE2↓, NF-kB↓, EMT↓, E-cadherin↑, Vim↓, Fibronectin↓, N-cadherin↓,
1116- GI,    6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway
- in-vitro, Colon, Caco-2 - in-vitro, CRC, HCT116
TumCG↓, Apoptosis↑, TumCMig↓, MMP2↓, N-cadherin↓, IKKα↓, p‑NF-kB↓, Snail↓, VEGF↓,
4505- GLA,    Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α
- in-vitro, NSCLC, Calu-1
TumCP↓, PCNA↓, Ki-67↓, MCM2↓, Bcl-2↓, BAX↑, cl‑Casp3↑, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓,
858- Gra,    Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116
TumCCA↑, Apoptosis↑, ROS↑, MMP↓, Cyt‑c↑, Casp↑, BAX↑, Bcl-2↓, TumCMig↓, TumCI↓,
2511- H2,    Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation
- in-vivo, GBM, U87MG
TumCG↓, OS↑, CD133↓, Ki-67↓, angioG↓, Diff↑, TumCMig↓, TumCI↓, Dose↝, BBB↑, mt-ROS↑,
1412- HCA,    Identification of ATP Citrate Lyase as a Positive Regulator of Glycolytic Function in Glioblastomas
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229
ACLY↓, TumCMig↓,
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
1087- HNK,    Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460 - in-vitro, Lung, H226
TumCMig↓, COX2↓, PGE2↓, NF-kB↓, p65↓, β-catenin/ZEB1↓, MMP2↓, MMP9↓,
2894- HNK,    Pharmacological features, health benefits and clinical implications of honokiol
- Review, Var, NA - Review, AD, NA
*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, FOXM1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1/CCND1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,
2882- HNK,    Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
- in-vitro, PC, PANC1
TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,
2884- HNK,    Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP
- in-vitro, Lung, A549 - in-vitro, Lung, H460
EMT↓, cFLIP↓, N-cadherin↓, Snail↓, p‑SMAD2↓, p‑SMAD3↓, IKKα↑, TumCMig↓,
2898- HNK,    Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism
- in-vitro, GC, AGS - in-vitro, GC, NCI-N87 - in-vitro, BC, MGC803 - in-vitro, GC, SGC-7901
TumCP↓, Apoptosis↑, TumCI↓, TumCMig↓, HER2/EBBR2↓, TumCCA↑, PI3K↓, Akt↓, MMP9↓, P21↑,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2874- HNK,    Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6‐mediated matrix metalloproteinase 9
- in-vitro, Lung, H1299
MMP9↓, α-tubulin↑, TumCI↓, HDAC6↓, HSP90↓, TumCMig↓, EGFR↓,
2878- HNK,    Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9
- in-vitro, Lung, H1299
TumCMig↓, TumCI↓, MMP9↓, α-tubulin↑, HDAC6↓, HSP90↓,
4632- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, SUM159
CSCs↓, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, Wnt↓, p‑LRP6↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, SMAD2↓, SMAD3↓, TGF-β↓,
4636- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/ß-catenin and TGFß signaling
- in-vitro, BC, SUM159 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, BC, BT549
Wnt↓, β-catenin/ZEB1↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, TGF-β↓, CSCs↓, TumCMig↓, chemoP↑,
4637- HT,    Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells
- in-vitro, Nor, RWPE-1 - in-vitro, Pca, LNCaP - in-vitro, Pca, 22Rv1 - in-vitro, Pca, PC3
selectivity↑, TumCMig↓, p‑Akt↓, ROS↑, CSCs↓, CD44↓, TumCP↓,
1278- I3C,    Indole-3-carbinol inhibits prostate cancer cell migration via degradation of beta-catenin
- in-vivo, Pca, DU145
TumCMig↓, β-catenin/ZEB1↓,
1920- JG,  TQ,  Plum,    Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line
- in-vitro, PC, PANC1
ROS↑, TumCMig↓, MMP9↓,
1924- JG,    Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway
- in-vitro, Lung, A549
TumCMig↓, TumCI↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, BAX↑, Cyt‑c↑, ROS↑, MDA↑, GPx4↓, SOD↓, PI3K↓, Akt↓, eff↓,
1266- LE,    Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,
1171- LT,    The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma
- in-vitro, CCA, NA
Wnt↓, TumCCA↑, Apoptosis↑, TumCMig↓, β-catenin/ZEB1↓, cMyc↓, cycD1/CCND1↓,
1125- LT,    Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity
- in-vitro, BC, NA
YAP/TEAD↓, TAZ↓, MSCmark↓, EM↑, TumCMig↓,
4687- LT,  QC,    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells
- in-vitro, Pca, DU145
CSCs↓, EMT↓, MMPs↓, TumCMig↓, TumCI↓,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,
3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, P21↑, P53↑, GSK‐3β↓, p27↓, Akt↓, mTOR↓, ROS↓, MMPs↓, TumCI↓, TumCMig↓, NF-kB↓, *iNOS↓, *COX2↓, lipid-P↓, GSH↑, NRF2↑,
4782- Lyco,    New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, TumCI↓, TumCA↓, ROS↓, MMP2↓, MMP7↓, MMP9↓, VEGF↓, E-cadherin↑, TIMP1↑, TIMP2↑, BioAv↝, *IL12↓, *TNF-α↓, *IL1↓, *IL1β↓, *IL6↓, COX2↓, iNOS↓, *radioP↑, NF-kB↓, survivin↓, Casp3↑, Bax:Bcl2↑,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
1196- MAG,    2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
- in-vitro, HCC, NA
TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
4531- MAG,    Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway
- in-vitro, CRC, HCT116
Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, p‑AMPK↑, Bcl-2↓, P53↑, BAX↑, Cyt‑c↑, TumCMig↓, TumCI↓,
4528- MAG,    Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
- Review, Nor, NA
*Inflam↑, *cardioP↑, *angioG↓, *antiOx↑, *neuroP↑, *Bacteria↓, AntiTum↑, TumCG↓, TumCMig↓, TumCI↓, Apoptosis↑, E-cadherin↑, NF-kB↓, TumCCA↑, cycD1/CCND1↓, PCNA↓, Ki-67↓, MMP2↓, MMP7↓, MMP9↓, TumCG↓, Casp3↑, NF-kB↓, Akt↓, mTOR↓, LDH↓, Ca+2↑, eff↑, *toxicity↓, *BioAv↝, *PGE2↓, *TLR2↓, *TLR4↓, *MAPK↓, *PPARγ↓,
4527- MAG,    Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway
- in-vitro, ESCC, TE1 - in-vitro, ESCC, Eca109 - vitro+vivo, SCC, KYSE150
TumCP↓, TumCMig↓, MMP2↓, Apoptosis↑, cl‑Casp3↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑p38↓, TumCG↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
4515- MAG,    Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight
- Review, Var, NA
AntiCan↑, TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↑, angioG↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, NF-kB↓,
1063- MEL,    HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
AntiCan↑, TumCMig↓, GSH↓, Casp3↑, Apoptosis↑, ROS↑, HDAC1↓, Ac-histone H3↑, PUMA↑, BAX↑, PCNA↓, Bcl-2↓,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2↓,
1066- MET,    Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma
- in-vitro, SCC, NA
PDH↑, Hif1a↓, TumCMig↓, Casp3↑, P53∅,
2249- MF,    Pulsed electromagnetic fields modulate energy metabolism during wound healing process: an in vitro model study
- in-vitro, Nor, L929
*TumCMig↑, *tumCV↑, *Glycolysis↑, *ROS↓, *mitResp↓, *other↝, *OXPHOS↓, *pH↑, *antiOx↑, *PFKM↑, *PFKL↑, *PKM2↑, *HK2↑, *GLUT1↑, *GPx1↑, *GPx4↑, *SOD1↑,
4354- MF,  doxoR,    Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF-7
selectivity↑, Apoptosis↑, TumCI↓, tumCV↓, TumVol↓, eff↓, eff↑, ROS↑, Ca+2↑, TumCMig↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
3500- MF,    Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress
- in-vitro, Ovarian, SKOV3
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
3470- MF,    Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression
- in-vitro, Cerv, HeLa
TNF-α↑, IL6↑, ROS↑, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓,
524- MF,    Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs)
- vitro+vivo, PC, MS-1 - vitro+vivo, PC, HUVECs
other↓, TumCP↓, TumCMig↓, VEGFR2↓, TumVol↓, HSP70/HSPA5↓, HSP90↓, TumCCA↑, angioG↓,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,
1128- Myr,    Myricetin suppresses TGF-β-induced epithelial-to-mesenchymal transition in ovarian cancer
- vitro+vivo, Ovarian, NA
MAPK↓, ERK↓, PI3K↓, Akt↓, p‑PARP↑, cl‑Casp3↑, Bax:Bcl2↑, TumCMig↓, SMAD3↓,
1805- NarG,    Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota
- in-vitro, Ovarian, A2780S - in-vivo, NA, NA
TumCP↓, TumCMig↓, PI3K↓, TumVol↓, TumW↓, BioAv↑, GutMicro↑, Dose∅, eff↑, EGFR↓, cycD1/CCND1↓, toxicity∅,
1267- NCL,    Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression
- in-vitro, HCC, NA
TumCP↓, cycD1/CCND1↓, MMP9↓, TumCMig↓,
4976- Nimb,    Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition
- vitro+vivo, PC, NA
ROS↑, Apoptosis↑, TumAuto↑, TumCP↓, TumCMig↓, TumCI↓, EMT↓, Dose↓, selectivity↑, Akt↓, eff↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓,
4974- Nimb,    Nimbolide Induces ROS-Regulated Apoptosis and Inhibits Cell Migration in Osteosarcoma
- in-vitro, OS, NA
Apoptosis↑, ER Stress↑, mtDam↑, ROS↑, Casp↑, TumCMig↓, TumMeta↓,
1130- OA,    Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCI↓, TumCMig↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓,
1225- OLST,    Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway
- vitro+vivo, PC, NA
TumCMig↓, TumCI↓, Ferroptosis↑, MAPK↓,
1994- Part,    Parthenolide Inhibits Tumor Cell Growth and Metastasis in Melanoma A2058 Cells
- in-vitro, Melanoma, A2058 - in-vitro, Nor, L929
tumCV↓, selectivity?, ROS?, BAX↑, TumCCA?, MMP2↓, MMP9↓, TumCMig↓, eff↑,
2381- PBG,    Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, angioG↓, TNF-α↓, IL1β↓, IL6↓, NLRP3↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ROS↑, MMP↓,
1664- PBG,    Anticancer Activity of Propolis and Its Compounds
- Review, Var, NA
Apoptosis↑, TumCMig↓, TumCCA↑, TumCP↓, angioG↓, P21↑, p27↑, CDK1↓, p‑CDK1↓, cycA1/CCNA1↓, CycB/CCNB1↓, P70S6K↓, CLDN2↓, HK2↓, PFK↓, PKM2↓, LDHA↓, TLR4↓, H3↓, α-tubulin↓, ROS↑, Akt↓, GSK‐3β↓, FOXO3↓, NF-kB↓, cycD1/CCND1↓, MMP↓, ROS↑, i-Ca+2↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, BAX↑, PUMA↑, ROS↑, MMP↓, Cyt‑c↑, cl‑Casp8↑, cl‑Casp8↑, cl‑Casp3↑, cl‑PARP↑, eff↑, eff↑, RadioS↑, ChemoSen↑, eff↑,
1663- PBG,    Propolis and Their Active Constituents for Chronic Diseases
- Review, Var, NA
NF-kB↓, Casp↓, Fas↓, DNAdam↑, Casp3↑, P53↝, MMP↝, ROS↑, mtDam↑, Dose?, angioG↓, TumCP↓, TumCMig↓, BAX↑, selectivity↑, MMP↓, LDH↓, IL6↓, IL1β↓, TNF-α↓,
1231- PBG,    Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, MMP↓, TLR4↓, TNF-α↓, NF-kB↓, IL1β↓, IL6↓, IRAK4↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ACC↓, FASN↓, eff↓,
4933- PEITC,    Phenethyl isothiocyanate inhibits metastasis potential of non-small cell lung cancer cells through FTO mediated TLE1 m6A modification
- vitro+vivo, Lung, H1299 - vitro+vivo, SCC, H226
AntiCan↓, TumCP↓, TumMeta↓, ChemoSen↑, tumCV↓, TumCI↓, TumCMig↓, FTO↓, TLE1↓, Akt↓, NF-kB↓,
4939- PEITC,    Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo
- in-vitro, Pca, PC3 - ex-vivo, Nor, HUVECs
Risk↓, angioG↓, VEGF↓, TumCMig↓, Akt↓, EGF↓, TumCMig↓,
4926- PEITC,    PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT
- in-vitro, CRC, SW48
TumCI↓, TumCMig↓, EMT↓, Smad1↓, AntiCan↑, Snail↓, Slug↓, Zeb1↓, ZEB2↓, TGF-β1↓, eff↑, E-cadherin↑, N-cadherin↓, Vim↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
4941- PEITC,    PEITC: A resounding molecule averts metastasis in breast cancer cells in vitro by regulating PKCδ/Aurora A interplay
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
PKCδ↑, Apoptosis↓, selectivity↑, tumCV↓, p‑NRF2↑, cl‑PARP1↑, TumCMig↓, ROS↓, Hif1a↓,
1256- PI,    Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
- in-vitro, adrenal, PHEO - in-vivo, NA, NA
Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,
1016- PI,    Piperine suppresses the Wnt/β-catenin pathway and has anti-cancer effects on colorectal cancer cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW480 - in-vitro, CRC, DLD1
β-catenin/ZEB1↓, Wnt↓, TumCP↓, TumCMig↓,
1131- PI,    Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549
TumCG↓, tumCV↓, TumCMig↓, TumCI↓, MMP2↓, Slug↓, N-cadherin↓, β-catenin/ZEB1↓, SMAD3↓, E-cadherin↑, EMT↓,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP↑, Dose↝,
2961- PL,    Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis
- in-vitro, ESCC, KYSE-30
Pyro↑, TumCP↓, TumCMig↓, TumCI↓, ASC↑, cl‑Casp1↑, NLRP3↑, GSDMD↑, ROS↑, NRF2↓, TXNIP↑,
2957- PL,    Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCP↓, TumCMig↓, TumCCA↑, ROS↑, H2O2↑, GSH↓, IKKα↓, NF-kB↓, P21↑, eff↓,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24 - in-vivo, Bladder, NA
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2945- PL,    Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
- in-vitro, CRC, HCT116
ROS↑, SMAD4↑, ChemoSen↑, P53↑, P21↑, BAX↑, Bcl-2↓, survivin↓, TumCMig↓,
4968- PSO,    Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer
- in-vitro, Cerv, NA
*Inflam↓, *antiOx↑, *neuroP↑, *AntiDiabetic↑, *Bacteria↓, AntiTum↑, CSCs↓, ROS↑, TumAuto↑, Apoptosis↑, ChemoSen↑, RadioS↑, BioAv↓, *cardioP↑, *ROS↓, *LDH↓, TumCP↓, TRAIL⇅, TumCMig↓, EMT↓, NF-kB↓, P53↑, Casp3↑, NOTCH↓, CSCs↓, angioG↓, VEGF↓, Ki-67↓, CD31↓, TRAILR↑, MMP↓, BioAv↓, BioAv↑,
4965- PSO,  Cisplatin,    The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis
- vitro+vivo, GC, HGC27 - vitro+vivo, GC, MKN45
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, *toxicity↓, eff↑, Ferroptosis↑, ACSL4↑, GPx4↓, ChemoSen↑, chemoP↑, AntiTum↑, Sepsis↓,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
2408- PTS,    Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway
- in-vitro, ESCC, NA
TumCP↓, TumCMig↓, PKA↓, GlucoseCon↓, lactateProd↓, PKM2↓, STAT3↓, cMyc↓,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
1238- PTS,    Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention
- in-vitro, GC, NA - in-vivo, NA, NA
TumCCA↑, TumCP↓, TumCMig↓, TumCI↓, TumVol↓, TumW↓, Weight∅, JAK2↓, STAT3↓,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,
3374- QC,    Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis
- Review, Oral, NA - Review, AD, NA
α-SMA↓, α-SMA↑, TumCP↓, tumCV↓, TumVol↓, TumCI↓, TumMeta↓, TumCMig↓, ROS↑, Apoptosis↑, BioAv↓, *neuroP↑, *antiOx↑, *Inflam↓, *Aβ↓, *cardioP↑, MMP↓, Cyt‑c↑, MMP2↓, MMP9↓, EMT↓, MMPs↓, Twist↓, Slug↓, Ca+2↑, AIF↑, Endon↑, P-gp↓, LDH↑, HK2↓, PKA↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GRP78/BiP↑, Casp12↑, CHOP↑,
3373- QC,    The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway
- in-vitro, Pca, DU145
TumCP↓, Casp3↑, Bcl-2↓, Apoptosis↑, TumCI↓, TumCMig↓, CXCL12↓, CXCR4↓,
3371- QC,    Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways
- in-vitro, GBM, T98G
TIMP2↑, TumCG↓, TumCMig↓, Apoptosis↑, TumCCA↑, MMP↓, ROS↑, Bax:Bcl2↑, cl‑Casp9↑, cl‑Casp3↑, DNAdam↑, γH2AX↑, MGMT↓, cl‑PARP↑,
3339- QC,    Quercetin suppresses ROS production and migration by specifically targeting Rac1 activation in gliomas
- in-vitro, GBM, C6 - in-vitro, GBM, IMR32
BBB↑, tumCV↓, TumCMig↓, Rac1↓, p66Shc↓, ROS↓,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
3070- RES,    Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma
- in-vitro, RCC, ACHN - in-vitro, RCC, 786-O - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
3072- RES,    Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway
- in-vitro, GBM, LN229 - in-vitro, GBM, U87MG
tumCV↓, TumCP↓, TumCMig↓, Apoptosis↑, NLRP3↓, JAK2↓, STAT3↓, IL1β↓, IL18↓, IL6↓, TNF-α↓, Inflam↓,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
3095- RES,    Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk
- in-vitro, BC, NA
TumCP↓, TumCMig↓, TumCI↓, cycD1/CCND1↓, cMyc↓, MMP2↓, MMP9↓, SOX2↓, Akt↓, STAT3↓, α-SMA↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
1048- RosA,  Ger,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2↓, PD-L1↓,
1747- RosA,    Molecular Pathways of Rosmarinic Acid Anticancer Activity in Triple-Negative Breast Cancer Cells: A Literature Review
- Review, BC, MDA-MB-231 - Review, BC, MDA-MB-468
TumCCA↑, TNF-α↑, GADD45A↑, BNIP3↑, survivin↓, Bcl-2↓, BAX↑, HH↓, eff↑, ChemoSen↑, RadioS↑, TumCP↓, TumCMig↓, Apoptosis↑, RenoP↑, CardioT↓,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3016- RosA,    Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling
- in-vitro, HNSCC, UM-SCC-6 - in-vitro, HNSCC, UM-SCC-10B
chemoP↓, EGF↓, tumCV↓, TumCMig↓, ROS↓, PI3K↓, Akt↓, ERK↓, antiOx↑, p‑EGFR↓,
3008- RosA,    Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells
- in-vitro, Melanoma, SK-MEL-28
tumCV↓, TumCMig↓, ROS↓, Casp3↑, selectivity↑, Casp8↑, NLRP3↓,
3035- RosA,    Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling
- in-vitro, PC, NA - in-vivo, NA, NA
Gli1↓, TumCCA↑, TumCMig↓, TumCI↓, CDK2↓, cycE/CCNE↓, P21↑, p27↑,
1132- RT,    Rutin Promotes Proliferation and Orchestrates Epithelial–Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
Vim↑, N-cadherin↑, E-cadherin↓, TumCP↑, TumCMig↑, tumCV↑, MKI67↑,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27↑, CHOP↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
5002- Sal,  SFN,    Salinomycin and Sulforaphane Exerted Synergistic Antiproliferative and Proapoptotic Effects on Colorectal Cancer Cells by Inhibiting the PI3K/Akt Signaling Pathway in vitro and in vivo
- in-vivo, CRC, Caco-2 - vitro+vivo, CRC, CX-1
Apoptosis↑, PI3K↓, Akt↓, P53↑, BAX↑, Bax:Bcl2↑, p‑PARP↑, TumCMig↓,
1209- SANG,    Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration
- in-vitro, Lung, A549
VEGF↓, TumCMig↓, Akt↓, p38↓,
1136- SFN,    Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells
- in-vitro, Lung, NA - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Snail↓, ERK5↑, EMT↓,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
1499- SFN,    Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway
- in-vitro, BC, NA
TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2↝, MMP2↝, MMP9↝,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
2166- SFN,    Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction
- in-vitro, Oral, NA - in-vivo, NA, NA
CSCs↓, selectivity↑, TumCMig↓, TumCI↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3306- SIL,  Rad,    Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation
- Review, Var, NA
radioP↑, RadioS↑, TumCMig↓, TumCI↓, angioG↓, Apoptosis↑, DNAdam↓, ROS↑, *ROS↓, *Inflam↓,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3330- SIL,    Mechanistic Insights into the Pharmacological Significance of Silymarin
- Review, Var, NA
*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,
3326- SIL,    Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway
- in-vitro, Liver, HepG2 - in-vitro, Liver, Hep3B
*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,
3322- SIL,    Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
2417- SK,    Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H446
TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,
3045- SK,    Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2)
- in-vitro, PC, MIA PaCa-2
ECAR↓, Glycolysis↓, ATP↓, PKM2↓, TumCMig↓, Ca+2↑, GlucoseCon↓, lactateProd↓, MMP↓, ROS↑,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
2190- SK,    Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway
- in-vitro, HCC, HCCLM3
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↓, ROS↑, OCR↓, ATP↓, PKM2↓,
2183- SK,    Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1
- in-vitro, Thyroid, TPC-1
TumCMig↓, TumCI↓, PTEN↑, DNMT1↓,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2210- SK,    Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway
- in-vitro, BC, MGC803
TumCA↓, TumCI↓, TumCMig↓, MMP2↓, MMP7↓, TLR2↓, p65↓, NF-kB↓, eff↑, ROS↑,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
338- SNP,    Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer
- vitro+vivo, Bladder, 5637
TumCD↑, Apoptosis↑, TumCMig↓, TumCP↓,
359- SNP,    Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Nor, HEK293
Casp3↑, Casp9↑, P53↑, ROS↑, MMP2↓, MMP9↓, TumCCA↑, *toxicity↓, TumCMig↓, TumCI↓,
4555- SNP,    Silver nanoparticles from Dendropanax morbifera Léveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2
*Bacteria↓, tumCV↓, selectivity↑, ROS↑, Apoptosis↑, TumCMig↓, AntiCan↑,
4416- SNP,    Efficacy of curcumin-synthesized silver nanoparticles on MCF-7 breast cancer cells
- in-vitro, BC, MCF-7
TumCMig↓, Apoptosis↑, BAX↑, P53↑, Bcl-2↓,
962- TQ,    Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways
- in-vitro, PC, PANC1 - in-vitro, Nor, hTERT-HPNE - in-vitro, PC, AsPC-1 - in-vitro, PC, Bxpc-3
TumCMig↓, TumCI↓, Apoptosis↑, Hif1a↓, PI3k/Akt/mTOR↓, TumCCA↑, *toxicity↓, *TumCI∅, *TumCMig∅,
3571- TQ,    The Role of Thymoquinone in Inflammatory Response in Chronic Diseases
- Review, Var, NA - Review, Stroke, NA
*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,
3418- TQ,    Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome
- in-vitro, Melanoma, A375 - in-vivo, NA, NA
TumMeta↓, TumCMig↓, NLRP3↓, Casp1↓, IL1β↓, IL18↓, ROS↓, NF-kB↓,
3421- TQ,    Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer
- Analysis, Nor, NA - in-vivo, Nor, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, HaCaT
HDAC↓, P21↑, Maspin↑, BAX↑, B2M↓, TumCCA↑, selectivity↑, *toxicity↓, TumCMig↓, TumCP↓,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
5017- UA,    Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells
- in-vitro, Cerv, INT-407 - in-vitro, CRC, HCT116
AntiCan↑, TumCG↓, ROS↑, Apoptosis↑, TumCMig↓, CTNNB1↓, Twist↓, Bcl-2↓, survivin↓, NF-kB↓, Sp1/3/4↓, BAX↑, P21↑, P53↑, eff↓, TumCMig↓,
5021- UA,    Anticancer effect of ursolic acid via mitochondria-dependent pathways
- Review, Var, NA
Inflam↓, TNF-α↓, IL6↓, IL17↓, NF-kB↓, COX2↓, *AntiDiabetic↑, *hepatoP↑, ALAT↓, AST↓, TumCP↓, Apoptosis↑, TumCCA↑, TumAuto↑, tumCV↓, TumCMig↓, Glycolysis↓, ATP↓, lactateProd↓, HK2↓, PKA↓, COX2↓, mtDam↑, Casp3↑, Casp8↑, Casp9↑, Akt↓, ROS↑, MMP↓, P53↑,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
4851- Uro,    Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1
- in-vitro, OS, MG63
TumCMig↓, TumCI↓, TumCA↑, MMP2?, MMP9?,
4849- Uro,    Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway
- vitro+vivo, GC, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, TumAuto↑, TumCG↓, chemoP↑, ChemoSen↑,
4847- Uro,    Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells
- in-vitro, CRC, SW-620
TumCP↓, TumCMig↓, MMP9↓, TumAuto↑, Apoptosis↑, TumCCA↓, TumMeta↓, ChemoSen↓,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
4842- Uro,    Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, MCF-7 - in-vitro, BC, 4T1
Inflam↓, IL6↓, TNF-α↓, eff↑, STAT3↓, TumCP↓, TumCMig↓,
1217- VitC,    High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition
- in-vitro, BC, Bcap37 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, Vim↓, EMT↓,
3143- VitC,  ATO,    Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis
- in-vitro, OS, NA
TumCP↓, TumCMig↓, TumCI↓, eff↑, Glycolysis↓, lactateProd↓, ATP↓, PGK1↓, PGM1↓, LDHA↓,
1820- VitK3,    Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1/CCND1↓, TumCCA↑,
1821- VitK3,    Menadione (Vitamin K3) induces apoptosis of human oral cancer cells and reduces their metastatic potential by modulating the expression of epithelial to mesenchymal transition markers and inhibiting migration
- in-vitro, Oral, NA - in-vitro, Nor, HEK293 - in-vitro, Nor, HaCaT
selectivity↑, TumCD↓, BAX↑, P53↑, Bcl-2↓, p65↓, E-cadherin↑, EMT↓, Vim↓, Fibronectin↓, TumCG↓, TumCMig↓,
1222- Z,    Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition
- in-vitro, Ovarian, NA
EMT↑, TumCMig↑, TumCI↑, ERK↑, Akt↑,
2414- β‐Ele,    Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 279

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

4-HNE↑, 1,   antiOx↓, 1,   antiOx↑, 3,   ATF3↑, 1,   Catalase↓, 1,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   ENOX2↓, 1,   ENOX2↑, 1,   Ferroptosis↑, 7,   GPx↓, 1,   GPx↑, 1,   GPx4↓, 4,   GSH↓, 14,   GSH↑, 1,   H2O2↑, 2,   HK1↓, 1,   HO-1↓, 5,   HO-1↑, 3,   Iron↑, 1,   Keap1↓, 1,   lipid-P↓, 2,   lipid-P↑, 4,   MDA↓, 1,   MDA↑, 4,   NOX4↓, 1,   NRF2↓, 5,   NRF2↑, 6,   p‑NRF2↑, 1,   OXPHOS↑, 1,   p66Shc↓, 1,   PARK2↑, 1,   PYCR1↓, 1,   ROS?, 1,   ROS↓, 14,   ROS↑, 81,   ROS⇅, 1,   ROS↝, 1,   ROS∅, 1,   mt-ROS↑, 2,   SIRT3↑, 1,   SOD↓, 5,   SOD1↓, 1,   SOD2↓, 1,   SOD2↑, 1,   Trx↓, 1,   TrxR1↓, 2,   xCT↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,   Ferritin↑, 1,   FTH1↓, 1,   NCOA4↑, 1,   Tf↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 8,   CDC2↓, 1,   CDC25↓, 2,   EGF↓, 3,   FGFR1↓, 3,   MEK↓, 1,   p‑MEK↓, 3,   MMP↓, 27,   MMP↑, 1,   MMP↝, 1,   MMP∅, 1,   mtDam↑, 7,   OCR↓, 4,   OCR↑, 1,   PINK1↑, 1,   Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   Ac-histone H3↑, 1,   ACC↓, 2,   ACLY↓, 1,   ACSL4↑, 1,   ALAT↓, 2,   ALDOA↓, 1,   AMPK↓, 1,   AMPK↑, 12,   AMPK↝, 1,   p‑AMPK↑, 5,   ATG7↑, 1,   CAIX↓, 1,   cMyc↓, 17,   CYP3A4↓, 1,   ECAR↓, 5,   FASN↓, 3,   FDG↓, 1,   GlucoseCon↓, 9,   Glycolysis↓, 16,   ac‑Histones↑, 1,   HK2↓, 8,   HMG-CoA↓, 1,   IDH1↑, 1,   IR↓, 1,   lactateProd↓, 11,   LDH↓, 3,   LDH↑, 1,   LDHA↓, 8,   LDHA∅, 1,   lipoGen↓, 1,   NADPH↓, 1,   PDH↑, 2,   PDH∅, 1,   PDHB↓, 1,   PDK1↓, 3,   p‑PDK1↓, 1,   PFK↓, 3,   PFKFB2↓, 1,   PGK1↓, 1,   PGM1↓, 1,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 18,   PKM2∅, 1,   PPARα↝, 1,   PPARγ↑, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   p‑S6↓, 1,   p‑S6K↓, 1,   SIRT1↓, 3,   SIRT1↑, 3,   SREBP1↓, 2,   TumCM/A↑, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 45,   Akt↑, 1,   p‑Akt↓, 19,   Apoptosis↓, 3,   Apoptosis↑, 101,   ATF2↓, 1,   BAD↑, 1,   Bak↑, 3,   BAX↓, 1,   BAX↑, 38,   BAX⇅, 1,   Bax:Bcl2↑, 8,   Bcl-2↓, 40,   Bcl-xL↓, 5,   BIM↑, 1,   Casp↓, 1,   Casp↑, 10,   Casp1↓, 1,   cl‑Casp1↑, 1,   Casp10∅, 1,   Casp12↑, 2,   Casp2↑, 1,   Casp3↓, 1,   Casp3↑, 28,   cl‑Casp3↑, 15,   Casp7↑, 1,   Casp8↑, 8,   Casp8∅, 1,   cl‑Casp8↑, 3,   Casp9↑, 13,   cl‑Casp9↑, 5,   CBP↓, 1,   cFLIP↓, 3,   Chk2↑, 1,   CK2↓, 2,   Cyt‑c↑, 17,   DR4↑, 1,   DR4∅, 1,   DR5↑, 2,   DR5∅, 1,   Endon↑, 1,   FADD∅, 1,   Fas↓, 1,   Fas↑, 5,   Ferroptosis↑, 7,   GRP58↓, 1,   GSDMD↑, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   IAP2↓, 1,   iNOS↓, 2,   JNK↑, 6,   p‑JNK↑, 1,   MAPK↓, 11,   MAPK↑, 4,   p‑MAPK↑, 1,   Mcl-1↓, 2,   Mcl-1↑, 1,   MDM2↑, 1,   Myc↓, 2,   Myc↑, 1,   Necroptosis↑, 2,   necrosis↑, 3,   NOXA↑, 1,   p27↓, 1,   p27↑, 6,   p38↓, 2,   p38↑, 4,   p‑p38↓, 2,   p‑p38↑, 2,   PUMA↑, 3,   Pyro↑, 1,   RIP1↓, 1,   survivin↓, 11,   Telomerase↓, 4,   TRAIL⇅, 1,   TRAILR↑, 1,   TumCD↓, 1,   TumCD↑, 4,   YAP/TEAD↓, 2,   β-TRCP↑, 1,  

Kinase & Signal Transduction ⓘ

EF-1α↓, 1,   HER2/EBBR2↓, 3,   p‑p70S6↓, 1,   Sp1/3/4↓, 6,   TSC2↑, 1,   p‑TSC2↑, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 1,   EZH2↓, 1,   H3↓, 1,   H3↑, 1,   ac‑H3↓, 1,   H4↑, 1,   ac‑H4↓, 1,   HATs↓, 2,   HATs↑, 3,   miR-145↑, 1,   miR-192-5p↑, 1,   miR-205↑, 1,   miR-21↓, 2,   miR-30a-5p↑, 1,   other↓, 1,   other↝, 1,   p‑pRB↓, 1,   TLE1↓, 1,   tumCV↓, 33,   tumCV↑, 1,   YMcells↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 5,   cl‑CHOP↑, 1,   eIF2α↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 11,   GRP78/BiP↓, 1,   GRP78/BiP↑, 6,   HSP70/HSPA5↓, 2,   HSP90↓, 4,   IRE1↑, 1,   PERK↑, 2,   p‑PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↓, 1,   Beclin-1↑, 1,   BNIP3↑, 1,   LAMP2↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3B↓, 1,   LC3B-II↑, 1,   LC3I↑, 1,   LC3II↓, 1,   LC3II↑, 4,   p62↓, 2,   p62↑, 1,   p‑p62↑, 1,   TumAuto↑, 12,  

DNA Damage & Repair ⓘ

ATM↑, 1,   ATR↑, 2,   CHK1↓, 1,   CHK1↑, 1,   DNAdam↓, 1,   DNAdam↑, 15,   DNMT1↓, 2,   DNMT1↑, 1,   DNMTs↓, 1,   GADD45A↑, 2,   MGMT↓, 1,   P53?, 1,   P53↑, 27,   P53↝, 1,   P53∅, 1,   p‑P53↑, 3,   ac‑P53↑, 1,   p73↑, 1,   PARP↓, 1,   PARP↑, 2,   p‑PARP↑, 2,   cl‑PARP↑, 14,   cl‑PARP1↑, 1,   PCLAF↓, 1,   PCNA↓, 7,   RAD51↓, 1,   γH2AX↑, 4,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK1↑, 1,   p‑CDK1↓, 1,   CDK2↓, 9,   CDK2↑, 1,   CDK4↓, 12,   CDK4↑, 2,   CDK4∅, 1,   Cyc↓, 2,   cycA1/CCNA1↓, 3,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 4,   cycD1/CCND1↓, 27,   cycD1/CCND1∅, 1,   cycE/CCNE↓, 7,   P21?, 1,   P21↓, 1,   P21↑, 20,   RB1↑, 2,   p‑RB1↓, 2,   TumCCA?, 1,   TumCCA↓, 3,   TumCCA↑, 64,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   ALDH↓, 2,   ALDH1A1↓, 1,   AXIN1↑, 1,   BMI1↓, 2,   CD133↓, 8,   CD24↓, 3,   CD44↓, 6,   cFos↓, 1,   cMET↓, 1,   p‑cMET↑, 1,   CSCs↓, 18,   CTNNB1↓, 1,   Diff↓, 1,   Diff↑, 2,   EMT↓, 69,   EMT↑, 1,   ERK↓, 20,   ERK↑, 6,   ERK↝, 1,   p‑ERK↓, 10,   p‑ERK⇅, 1,   ERK5↑, 1,   FGF↓, 2,   FGF↑, 1,   FGFR2↓, 1,   FOXM1↓, 3,   FOXO↑, 1,   FOXO3↓, 1,   FOXO3↑, 2,   Gli1↓, 4,   GREM1↓, 1,   GSK‐3β↓, 3,   GSK‐3β↑, 1,   HDAC↓, 10,   HDAC1↓, 3,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   HDAC6↓, 2,   HDAC8↓, 1,   HH↓, 2,   IGF-1↓, 3,   IGFBP3↑, 2,   p‑IGFR↓, 1,   Let-7↑, 1,   LRP6↓, 3,   p‑LRP6↓, 2,   MCM2↓, 1,   miR-34a↑, 3,   miR-99↑, 1,   MSCmark↓, 1,   mTOR↓, 26,   mTOR↑, 3,   mTOR↝, 1,   p‑mTOR↓, 7,   mTORC1↓, 3,   mTORC2↓, 1,   mTORC2↑, 1,   Nanog↓, 4,   Nestin↓, 3,   NOTCH↓, 3,   NOTCH1↓, 4,   NOTCH1↝, 1,   NOTCH3↓, 1,   OCT4↓, 4,   p300↓, 2,   P70S6K↓, 1,   p‑P70S6K↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 31,   p‑PI3K↓, 5,   PTCH1↓, 1,   PTEN↑, 8,   RAS↓, 2,   RAS↑, 1,   Shh↓, 2,   Smo↓, 2,   SOX2↓, 5,   Src↓, 3,   STAT↓, 2,   STAT3↓, 21,   STAT3↑, 1,   p‑STAT3↓, 5,   p‑STAT3↑, 1,   STAT6↓, 1,   TAZ↓, 1,   TCF-4↓, 1,   TOP1↓, 1,   TOPflash↓, 1,   TumCG↓, 37,   TumCG↑, 1,   tyrosinase↓, 1,   Wnt↓, 14,   Wnt/(β-catenin)↓, 4,   ZFX↓, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   AP-1↓, 1,   AP-1↝, 1,   CA↓, 1,   Ca+2↑, 13,   i-Ca+2↓, 1,   i-Ca+2↑, 1,   CD31↓, 1,   CDK4/6↓, 1,   CDKN1C↑, 1,   CLDN1↓, 2,   CLDN2↓, 1,   COL1A1↓, 1,   COL3A1↓, 1,   CXCL12↓, 1,   E-cadherin↓, 6,   E-cadherin↑, 45,   EM↑, 1,   F-actin↓, 3,   FAK↓, 8,   p‑FAK↓, 3,   Fibronectin↓, 2,   FTO↓, 1,   Galectin-9↓, 1,   GLI2↓, 1,   ITGB1↓, 3,   ITGB4↓, 1,   ITGB6↓, 1,   Ki-67↓, 9,   MET↓, 1,   MET↑, 1,   miR-130a↓, 2,   miR-139-5p↑, 1,   miR-203↑, 1,   miR-206↑, 1,   MMP1↓, 2,   MMP13↓, 1,   MMP17↓, 1,   MMP2?, 1,   MMP2↓, 44,   MMP2↝, 1,   MMP3↓, 2,   MMP7↓, 7,   MMP9?, 1,   MMP9↓, 49,   MMP9↝, 1,   MMPs↓, 13,   N-cadherin?, 1,   N-cadherin↓, 29,   N-cadherin↑, 1,   NEDD9↓, 3,   p‑pax↓, 1,   PDGF↓, 3,   PKA↓, 3,   PKCδ↓, 1,   PKCδ↑, 1,   Rac1↓, 1,   RHBDD1↓, 1,   Rho↓, 3,   Rho↑, 1,   RIP3↓, 1,   ROCK1↓, 1,   ROCK1↑, 1,   Slug↓, 14,   Smad1↓, 1,   SMAD2↓, 2,   p‑SMAD2↓, 12,   SMAD3↓, 6,   p‑SMAD3↓, 10,   SMAD4↓, 2,   SMAD4↑, 1,   Snail↓, 25,   SOX4↓, 1,   T-cadherin↑, 1,   TET1↑, 2,   TGF-β↓, 15,   TGF-β1↓, 1,   TIMP1↓, 2,   TIMP1↑, 6,   TIMP2↓, 1,   TIMP2↑, 4,   TIMP3↑, 1,   Treg lymp↓, 1,   TSP-1↑, 1,   TumCA↓, 4,   TumCA↑, 1,   TumCI?, 1,   TumCI↓, 159,   TumCI↑, 1,   TumCMig↓, 274,   TumCMig↑, 5,   TumCP↓, 116,   TumCP↑, 2,   TumMeta↓, 20,   Twist↓, 10,   TXNIP↑, 1,   uPA↓, 8,   VCAM-1↓, 1,   Vim↓, 37,   Vim↑, 1,   vinculin↓, 1,   Zeb1↓, 12,   Zeb1↑, 1,   ZEB2↓, 1,   ZO-1↓, 1,   ZO-1↑, 5,   α-SMA↓, 3,   α-SMA↑, 1,   α-tubulin↓, 1,   α-tubulin↑, 2,   ac‑α-tubulin↑, 1,   β-catenin/ZEB1↓, 28,   β-catenin/ZEB1↑, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 33,   angioG↑, 1,   ATF4↑, 2,   ECM/TCF↓, 1,   EGFR↓, 17,   p‑EGFR↓, 2,   EGR4↓, 1,   EPR↑, 1,   HIF-1↓, 2,   Hif1a↓, 25,   Hif1a↑, 1,   Hif1a↝, 1,   LOX1↓, 1,   NO↓, 1,   TAMS↓, 1,   VEGF↓, 31,   VEGFR2↓, 5,  

Barriers & Transport ⓘ

AQPs↓, 1,   BBB↑, 2,   GLUT1↓, 6,   GLUT1∅, 1,   GLUT3↓, 1,   GLUT3∅, 1,   NHE1↓, 1,   P-gp↓, 4,  

Immune & Inflammatory Signaling ⓘ

ASC↑, 1,   B2M↓, 1,   CD25+↓, 1,   CD4+↓, 1,   COX2↓, 20,   COX2↝, 1,   CXCc↓, 1,   CXCR4↓, 7,   FoxP3+↓, 1,   HMGB1↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 4,   IKKα↑, 1,   p‑IKKα↓, 1,   IL1↓, 3,   IL17↓, 1,   IL18↓, 3,   IL1α↓, 1,   IL1β↓, 7,   IL2↓, 2,   IL4↓, 1,   IL6↓, 8,   IL6↑, 1,   IL8↓, 2,   Imm↑, 1,   Inflam↓, 9,   IRAK4↓, 1,   p‑IκB↑, 1,   JAK↓, 2,   JAK2↓, 5,   p‑JAK2↓, 1,   LIF↑, 1,   MCP1↓, 1,   NF-kB↓, 47,   NF-kB↑, 2,   p‑NF-kB↓, 2,   p65↓, 6,   p‑p65↓, 1,   PD-1↓, 2,   PD-L1↓, 3,   PD-L1↑, 2,   PD-L2↓, 1,   PGE2↓, 7,   PSA↓, 3,   T-Cell↑, 1,   TILs↑, 1,   TLR2↓, 1,   TLR4↓, 3,   TNF-α↓, 10,   TNF-α↑, 2,  

Cellular Microenvironment ⓘ

pH↑, 1,   TIM-3↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 6,   NLRP3↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 5,   CDK6↓, 5,   CDK6↑, 2,   CDK6∅, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 9,   BioAv↑, 9,   BioAv↝, 2,   BioEnh?, 1,   ChemoSen↓, 1,   ChemoSen↑, 35,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose?, 2,   Dose↓, 2,   Dose↝, 10,   Dose∅, 5,   eff↓, 15,   eff↑, 49,   eff↝, 3,   Half-Life↓, 3,   Half-Life↑, 1,   Half-Life↝, 4,   P450↓, 1,   RadioS↑, 12,   selectivity?, 1,   selectivity↑, 33,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AR↓, 5,   AST↓, 2,   B2M↓, 1,   BMPs↑, 2,   EGFR↓, 17,   p‑EGFR↓, 2,   EZH2↓, 1,   Ferritin↓, 1,   Ferritin↑, 1,   FOXM1↓, 3,   GutMicro↑, 2,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 1,   IL6↓, 8,   IL6↑, 1,   Ki-67↓, 9,   LDH↓, 3,   LDH↑, 1,   Maspin↑, 1,   Myc↓, 2,   Myc↑, 1,   PD-L1↓, 3,   PD-L1↑, 2,   PSA↓, 3,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiCan↑, 13,   AntiTum↓, 1,   AntiTum↑, 5,   cardioP↑, 1,   CardioT↓, 1,   chemoP↓, 1,   chemoP↑, 10,   ChemoSideEff↓, 1,   hepatoP↑, 2,   MKI67↑, 1,   NDRG1↑, 1,   neuroP↑, 2,   OS↑, 8,   radioP↑, 2,   RenoP↑, 1,   Risk↓, 4,   toxicity?, 1,   toxicity↝, 1,   toxicity∅, 2,   TumVol↓, 14,   TumW↓, 7,   Weight∅, 2,  

Infection & Microbiome ⓘ

CD8+↑, 1,   Sepsis↓, 1,  
Total Targets: 686

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 20,   Catalase↑, 4,   GPx↑, 2,   GPx1↑, 2,   GPx4↑, 1,   GSH↑, 4,   GSTs↑, 3,   HDL↑, 1,   HO-1↑, 1,   Keap1↓, 1,   Keap1↑, 1,   lipid-P↓, 4,   MDA↓, 1,   MPO↓, 3,   NRF2↑, 5,   OXPHOS↓, 1,   ROS↓, 19,   ROS↑, 1,   SAM-e↑, 1,   SIRT3↑, 1,   SOD↑, 4,   SOD1↑, 2,   SOD2↑, 1,   TAC↑, 1,   TBARS↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↝, 1,   mitResp↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,   GlucoseCon↑, 1,   Glycolysis↑, 1,   H2S↑, 1,   HK2↑, 1,   LDH↓, 4,   NAD↑, 1,   NAD↝, 1,   NADPH↓, 1,   PFKL↑, 1,   PFKM↑, 1,   PKM2↑, 1,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Casp3↓, 2,   Fas↓, 1,   iNOS↓, 4,   JNK↑, 1,   MAPK↓, 2,   Telomerase↓, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   other↓, 1,   other↑, 1,   other↝, 3,   tumCV↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   PI3K↓, 1,   PTEN↑, 1,  

Migration ⓘ

AntiAg↑, 2,   Ca+2↝, 2,   cal2↓, 1,   E-cadherin↑, 1,   F-actin↓, 1,   N-cadherin↓, 1,   p‑Rac1↓, 1,   Rho↓, 1,   serineP↓, 1,   Snail↓, 1,   TIMP1↓, 1,   TumCI∅, 1,   TumCMig↓, 1,   TumCMig↑, 1,   TumCMig∅, 1,   Vim↓, 1,   ZO-1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   NO↓, 1,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 4,   GLUT1↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 6,   IFN-γ↓, 2,   IKKα↑, 1,   IL1↓, 1,   IL10↓, 1,   IL12↓, 1,   IL1β↓, 3,   IL6↓, 6,   IL8↓, 1,   Inflam↓, 14,   Inflam↑, 1,   MyD88↓, 1,   NF-kB↓, 6,   PGE2↓, 3,   TLR2↓, 2,   TLR4↓, 2,   TNF-α↓, 6,   VitD↑, 1,  

Cellular Microenvironment ⓘ

pH↑, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 1,   ChAT↑, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 3,   BACE↓, 1,   NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

testos↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 9,   BioAv↑, 6,   BioAv↝, 3,   Dose↑, 1,   Dose↝, 4,   eff↑, 3,   Half-Life↓, 1,   Half-Life↝, 2,   Half-Life∅, 1,   P450↓, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   ALP↓, 1,   AST↓, 2,   BMD↑, 1,   BMPs↑, 1,   BP↓, 1,   Calcium↑, 1,   creat↓, 1,   GutMicro↑, 1,   hs-CRP↓, 1,   IL6↓, 6,   LDH↓, 4,   Mag↑, 1,   VitD↑, 1,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiCan↑, 1,   AntiDiabetic↑, 2,   cardioP↑, 10,   chemoP↑, 2,   ChemoSideEff↓, 1,   cognitive↓, 1,   cognitive↑, 2,   hepatoP↑, 7,   memory↑, 4,   neuroP↑, 17,   radioP↑, 1,   RenoP↑, 2,   Risk↓, 1,   toxicity↓, 12,   toxicity↝, 2,   toxicity∅, 8,  

Infection & Microbiome ⓘ

Bacteria↓, 3,   IRF3↓, 1,  
Total Targets: 155

Scientific Paper Hit Count for: TumCMig, Tumor cell migration
15 Curcumin
13 Shikonin
10 Honokiol
9 Berberine
9 Silymarin (Milk Thistle) silibinin
8 Resveratrol
8 Magnetic Fields
7 Betulinic acid
7 Thymoquinone
7 Magnolol
7 Sulforaphane (mainly Broccoli)
7 Urolithin
6 Apigenin (mainly Parsley)
6 Propolis -bee glue
6 Fisetin
6 Quercetin
6 Piperlongumine
6 Rosmarinic acid
5 Alpha-Lipoic-Acid
5 Ashwagandha(Withaferin A)
5 EGCG (Epigallocatechin Gallate)
5 Metformin
5 Phenethyl isothiocyanate
4 Artemisinin
4 Astaxanthin
4 Boron
4 Capsaicin
4 Luteolin
4 Pterostilbene
4 Silver-NanoParticles
3 Gemcitabine (Gemzar)
3 Baicalein
3 Radiotherapy/Radiation
3 Chrysin
3 Ferulic acid
3 Garcinol
3 HydroxyTyrosol
3 Lycopene
3 Piperine
2 Allicin (mainly Garlic)
2 Andrographis
2 Baicalin
2 Boswellia (frankincense)
2 Caffeic acid
2 5-fluorouracil
2 Deguelin
2 Disulfiram
2 Copper and Cu NanoParticlex
2 Ellagic acid
2 Emodin
2 Ginkgo biloba
2 Grapeseed extract
2 Juglone
2 Magnetic Field Rotating
2 Nimbolide
2 Psoralidin
2 Cisplatin
2 salinomycin
2 Ursolic acid
2 Vitamin C (Ascorbic Acid)
2 VitK3,menadione
1 dibenzyl trisulphide(DTS) from Anamu
1 Astragalus
1 Atorvastatin
1 Butyrate
1 Genistein (soy isoflavone)
1 selenomethionine
1 Paclitaxel
1 Cannabidiol
1 Celecoxib
1 Chlorogenic acid
1 chitosan
1 Selenium
1 Citric Acid
1 Oxaliplatin
1 Docosahexaenoic Acid
1 Evodiamine
1 erastin
1 Fucoidan
1 Shilajit/Fulvic Acid
1 Proanthocyanidins
1 Ginger/6-Shogaol/Gingerol
1 γ-linolenic acid (Borage Oil)
1 Graviola
1 Hydrogen Gas
1 HydroxyCitric Acid
1 Indole-3-carbinol
1 Plumbagin
1 Licorice
1 Melatonin
1 doxorubicin
1 immunotherapy
1 Myricetin
1 Naringin
1 Niclosamide (Niclocide)
1 Oroxylin A
1 Orlistat
1 Parthenolide
1 Germacranolide
1 Rutin
1 Sanguinarine
1 Arsenic trioxide
1 Zinc
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:326  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page